Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)

The summary for the Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3): The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The FOA will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

Federal Grant Title:	Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-16-065
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.242
CFDA Descriptions:	Mental Health Research Grants
Current Application Deadline:	Oct 24, 2018
Original Application Deadline:	Oct 24, 2018
Posted Date:	Dec 21, 2015
Creation Date:	Dec 21, 2015
Archive Date:	Nov 24, 2018
Total Program Funding:
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Special district governments
Small businesses
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
State governments
County governments
City or township governments
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-16-065.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...; • Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional...; • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...; • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)